1. Scrip

Where's the value in Pfizer's $17bn Hospira buy?

 
• By Mandy Jackson

With Pfizer's pending $17bn acquisition of Hospira there's a lot of interest in the target company's biosimilar portfolio, given the potential for cheaper copies of biological medicines to steal substantial market share from major drug makers, but the most valuable part of the deal for Pfizer could be the addition of Hospira's generic injectable products and manufacturing capabilities.

With Pfizer's pending $17bn acquisition of Hospira there's a lot of interest in the target company's biosimilar portfolio, given the potential for cheaper copies of biological medicines to steal substantial market share from major drug makers, but the most valuable part of the deal for Pfizer could be the addition of Hospira's generic injectable products and manufacturing capabilities.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.